Should Catheter Recall Require Action From Getinge (OM:GETI B) Investors?

• Getinge subsidiary Atrium Medical initiated a voluntary Class II recall in August 2026 for 256 PVC thoracic catheters in the US after a single lot showed out of specification bacterial endotoxin test results. The affected products were distributed nationwide, and the US FDA enforcement report now classifies the action as ongoing.
• The recall highlights how quality control issues can create operational friction for Getinge, including potential remediation costs and inventory write offs, as well as nearer term pressure on clinician trust in its critical care device portfolio.
• We will now see how Getinge's investment narrative around quality, compliance costs and recurring device demand could be affected by this catheter recall.

Pressure test Getinge's recall risk against peers by scanning a curated set of 221 resilient stocks with low risk scores that screen strongly on balance sheet strength and lower operational risk.

Getinge Investment Narrative Recap

To own Getinge, you need to be comfortable with a healthcare equipment group that leans on recurring demand in intensive care, operating rooms and sterilization, while working through ongoing cost and tariff headwinds. The current recall looks operationally small, given the single affected lot, but it touches directly on the existing quality and regulatory risk narrative.

The key near term swing factor remains execution on efficiency, tariffs and supply chain regionalization, rather than this catheter issue. The biggest risk still sits in broader quality and regulatory exposure across acute care therapies, where any pattern of incidents or tighter oversight could weigh on installed base growth and compliance spending.

There are no other recent company announcements to reframe this event, so it largely fits into the existing story around Getinge and quality systems. The recall is consistent with the earlier indication that quality and regulatory issues, particularly in critical care products, can restrict growth and keep compliance spend elevated.

For potential catalysts, a key angle is how effectively management can keep rolling out improved quality and process controls while still expanding higher margin software, services and Life Science offerings. Any indication that incident rates remain contained and that acute care therapies continue to contribute to recurring consumables demand would support the operational case in spite of this recall headline.

Getinge's current analyst narrative points to SEK 40.0b in revenue and SEK 4.0b in earnings by 2029, based on 5.3% yearly revenue growth and an earnings increase of about SEK 1.3b from SEK 2.7b today.

Uncover why Getinge's fair value indicates a 4% potential downside to its current price, leaving little room for error.

Exploring Other Perspectives

Some bullish analysts focus on a different angle for Getinge. They emphasised faster scaling of high margin products and recurring revenue, and they expect revenue of about SEK 41.2b and earnings near SEK 4.6b by 2029. Those forecasts were set before this catheter recall, so you should consider whether quality concerns could alter that optimistic script.

Explore 4 other Getinge fair value estimates, including one that suggests the potential for as much as 66% upside from the current price.

Reach Your Own Conclusion

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Getinge research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Getinge. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Getinge's overall financial health at a glance.

Looking For More Investment Ideas Beyond Getinge?

If this Getinge recall has sharpened your focus on risk and quality, it can help to widen the lens and compare it with other businesses that fit different profiles on value, income, and resilience.

• For investors who want potential upside with a margin of safety, scan a focused group of 197 high quality undervalued stocks that pair stronger fundamentals with cheaper-looking valuations.
• If capital preservation is front of mind, stress test your ideas against a list of solid balance sheet and fundamentals (202 results) to see which companies carry less financial strain on their books.
• For readers hunting for stocks that the wider market may be overlooking, sort through a curated pool of 618 high quality undiscovered gems that combine quality metrics with lower visibility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com